Literature DB >> 10029619

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.

G C Kaiser1, F Yan, D B Polk.   

Abstract

BACKGROUND & AIMS: Derivatives of 5-aminosalicylic acid (mesalamine) represent a mainstay in inflammatory bowel disease therapy, yet the precise mechanism of their therapeutic action is unknown. Because tumor necrosis factor (TNF)-alpha is important in the pathogenesis of inflammatory bowel disease, we investigated the effect of mesalamine on TNF-alpha-regulated signal transduction and proliferation in intestinal epithelial cells.
METHODS: Young adult mouse colon cells were studied with TNF-alpha, epidermal growth factor, or ceramide in the presence or absence of mesalamine. Proliferation was studied by hemocytometry. Mitogen-activated protein (MAP) kinase activation and IkappaBalpha expression were determined by Western blot analysis. Nuclear transcription factor kappaB (NF-kappaB) nuclear translocation was determined by confocal laser immunofluorescent microscopy.
RESULTS: The antiproliferative effects of TNF-alpha were blocked by mesalamine. TNF-alpha and ceramide activation of MAP kinase were inhibited by mesalamine, whereas epidermal growth factor activation of MAP kinase was unaffected. TNF-alpha-stimulated NF-kappaB activation and nuclear translocation and the degradation of Ikappa-Balpha were blocked by mesalamine.
CONCLUSIONS: Mesalamine inhibits TNF-alpha-mediated effects on intestinal epithelial cell proliferation and activation of MAP kinase and NF-kappaB. Therefore, it may function as a therapeutic agent based on its ability to disrupt critical signal transduction events in the intestinal cell necessary for perpetuation of the chronic inflammatory state.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029619      PMCID: PMC3606885          DOI: 10.1016/s0016-5085(99)70182-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  42 in total

1.  Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase.

Authors:  Y Hu; V Baud; M Delhase; P Zhang; T Deerinck; M Ellisman; R Johnson; M Karin
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

2.  Activation of nuclear factor kappa B inflammatory bowel disease.

Authors:  S Schreiber; S Nikolaus; J Hampe
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 3.  Role of NF-kappaB in immune and inflammatory responses in the gut.

Authors:  M F Neurath; C Becker; K Barbulescu
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

Review 4.  NF-kappa B: a lesson in family values.

Authors:  D Thanos; T Maniatis
Journal:  Cell       Date:  1995-02-24       Impact factor: 41.582

5.  Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta.

Authors:  Q Zhao; F S Lee
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

6.  Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation.

Authors:  M Delhase; M Hayakawa; Y Chen; M Karin
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

7.  NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176.

Authors:  L Ling; Z Cao; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

8.  Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate.

Authors:  E Zandi; Y Chen; M Karin
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

9.  Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: adenosine dependent and independent mechanisms.

Authors:  B N Cronstein; M Van de Stouwe; L Druska; R I Levin; G Weissmann
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

10.  zeta PKC induces phosphorylation and inactivation of I kappa B-alpha in vitro.

Authors:  M T Diaz-Meco; I Dominguez; L Sanz; P Dent; J Lozano; M M Municio; E Berra; R T Hay; T W Sturgill; J Moscat
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more
  61 in total

1.  Choosing Therapy on the Basis of Disease Classifications in Inflammatory Bowel Disease.

Authors:  Maria T. Abreu
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

Review 2.  Molecular basis of the potential of mesalazine to prevent colorectal cancer.

Authors:  Carmine Stolfi; Roberto Pellegrini; Eleonora Franze; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

3.  Inhibition of Clostridium difficile toxin A-induced colitis in rats by APAZA.

Authors:  Douglas C McVey; Rodger A Liddle; Jennifer Riggs-Sauthier; Nnochiri Ekwuribe; Steven R Vigna
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

4.  Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis.

Authors:  Jeffrey B Brown; Goo Lee; Elizabeth Managlia; Gery R Grimm; Ramanarao Dirisina; Tatiana Goretsky; Paul Cheresh; Nichole R Blatner; Khashayarsha Khazaie; Guang-Yu Yang; Linheng Li; Terrence A Barrett
Journal:  Gastroenterology       Date:  2009-10-29       Impact factor: 22.682

Review 5.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 6.  Has the risk of colorectal cancer in inflammatory bowel disease decreased?

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Medical management of crohn disease.

Authors:  Frank I Scott; Mark T Osterman
Journal:  Clin Colon Rectal Surg       Date:  2013-06

8.  Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection.

Authors:  C B Larmonier; J K Uno; Kang-Moon Lee; T Karrasch; D Laubitz; R Thurston; M T Midura-Kiela; F K Ghishan; R B Sartor; C Jobin; P R Kiela
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-25       Impact factor: 4.052

9.  Expression profiles of genes in Toll-like receptor-mediated signaling of broilers infected with Clostridium perfringens.

Authors:  Yang Lu; Aimie J Sarson; Joshua Gong; Huaijun Zhou; Weiyun Zhu; Zhumei Kang; Hai Yu; Shayan Sharif; Yanming Han
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

10.  Somatostatin limits intestinal ischemia-reperfusion injury in macaques via suppression of TLR4-NF-kappaB cytokine pathway.

Authors:  Hao Wu; Ling Liu; Qinghua Tan; Chunhui Wang; Meimei Guo; Yongmei Xie; Chengwei Tang
Journal:  J Gastrointest Surg       Date:  2009-01-29       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.